Zynex Stock

Zynex Current Liabilities

Delisted·Dec 23, 2025

The Current Liabilities of Zynex (ZYXI) as of Aug 25, 2026 is 26.64 M USD. In the previous year, Current Liabilities was 27.37 M USD — a change of -2.66% (lower).

Current Liabilities

26.64 MUSD

YoY

-2.66%

Last updated:

Current Liabilities of Zynex is 2026 26.64 M USD. Current Liabilities of Zynex was 2025 27.37 M USD. It decreases by -2.66% lower compared to the previous year.

The Zynex Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
4.93 M USD
Jan 1, 2018
7.90 M USD
Jan 1, 2019
8.15 M USD
Jan 1, 2020
14.94 M USD
Jan 1, 2021
32.88 M USD
Jan 1, 2022
32.59 M USD
Jan 1, 2023
27.37 M USD
Jan 1, 2024
26.64 M USD
The Zynex Current Liabilities history
YEARCurrent LiabilitiesYoY
26.64 MUSD-2.66%
27.37 MUSD-16.04%
32.59 MUSD-0.86%
32.88 MUSD+120.09%
14.94 MUSD+83.39%
8.15 MUSD+3.17%
7.90 MUSD+60.24%
4.93 MUSD-42.79%
8.61 MUSD+0.49%
8.57 MUSD-2.24%
8.77 MUSD-17.21%
10.59 MUSD-15.91%
12.59 MUSD+19.01%
10.58 MUSD+78.49%
5.93 MUSD+58.69%
3.74 MUSD-44.22%
6.70 MUSD+115.44%
3.11 MUSD+60.89%
1.93 MUSD+123.38%
864,886.00USD+10.58%
782,104.00USD-34.34%
1.19 MUSD-37.91%
1.92 MUSD+105.39%
934,042.00USD+28.60%
726,317.00USD
0.00USD
0.00USD
0.00USD
Access this data via the Eulerpool API

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zynex stock

Current Liabilities of Zynex is 26.64 M USD in 2026.

Current Liabilities of Zynex changed from 27.37 M USD to 26.64 M USD, representing a -2.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Zynex since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Zynex historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Zynex

All Key Metrics — Zynex